Paris IBD Center S.A.S.
- Address
- 25-27 Boulevard Victor Hugo, 92200 Neuilly-sur-Seine, France
Paris IBD Center S.A.S.
Paris IBD Center S.A.S. is a specialized clinical research facility dedicated to advancing the treatment of inflammatory bowel diseases. The center focuses on evaluating novel therapeutic approaches for patients with moderate to severe IBD, with particular expertise in conducting Phase II and III clinical trials investigating next-generation biologic therapies and immunomodulatory agents.
- Crohn's disease treatment development and endoscopic response assessment
- Ulcerative colitis induction therapy and clinical remission studies
- Novel biologic agents including interleukin-targeted therapies
The research center demonstrates significant expertise in evaluating safety and tolerability profiles of innovative medications during induction therapy phases, while utilizing advanced endoscopic scoring systems such as the Simple Endoscopy Score for Crohn's Disease (SES-CD). Their comprehensive approach to IBD clinical research encompasses both objective endoscopic improvements and patient-centered clinical remission outcomes, positioning them as a key contributor to the development of transformative therapies for inflammatory bowel disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Paris IBD Center S.A.S.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Efavaleukin Alfa for Induction Therapy in Moderately to Severely Active Ulcerative Colitis: A Phase 2 Randomized, Double-blind, Placebo-controlled Study | Amgen Inc. | Phase II | Not Recruiting | Mar 2022 | Aug 2024 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tulisokibart | 2 | Unknown | 2021-09-23 | 2021-11-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.